{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-23-000005","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2023-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.512545+00:00","generated_at":"2026-06-20T11:04:27.238436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"J&J Q4 sales fall 4.4% to $23.7B; adjusted EPS rises 10.3% to $2.35; 2023 guidance issued","bullets":["Q4 reported sales $23.7B, -4.4% YoY; operational growth ex-COVID vaccine +4.6%.","Q4 GAAP EPS $1.33 (down 24.9%); adjusted EPS $2.35 (+10.3%).","Full-year 2022 sales $94.9B (+1.3% reported); operational growth 6.1%.","FY2022 GAAP EPS $6.73 (-13.8%); adjusted EPS $10.15 (+3.6%).","2023 guidance: adj. operational sales growth ex-COVID vaccine +4.0%; adj. EPS ~$10.50 (+3.5%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-23-000005","json":"https://secwatch.observer/filing/0000200406-23-000005.json","markdown":"https://secwatch.observer/filing/0000200406-23-000005.md","text":"https://secwatch.observer/filing/0000200406-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/jnj-20230124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:04:27.238436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52bbe44f31b77a1ee9d94ec5ef198634ca671fc8","claim":"JOHNSON & JOHNSON reported the fourth quarter ended January 1, 2023 results: revenue $23.7 Billion, EPS $1.33.","evidence_excerpt":"• 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%* • 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended January 1, 2023"},{"label":"Revenue","value":"$23.7 Billion"},{"label":"EPS","value":"$1.33"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"828e7f5356a35d731a0eda9bc6dedaad1f3a0362","claim":"JOHNSON & JOHNSON reported 2023 results: revenue 4.0%, EPS $10.50. Guidance initiated.","evidence_excerpt":"Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"4.0%"},{"label":"EPS","value":"$10.50"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e140ece9dce87f60429a58d25f97063b236477a3","claim":"JOHNSON & JOHNSON reported the fiscal year ended January 1, 2023 results: revenue $94.9 Billion, EPS $6.73.","evidence_excerpt":"• 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%* • 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000005/0000200406-23-000005-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended January 1, 2023"},{"label":"Revenue","value":"$94.9 Billion"},{"label":"EPS","value":"$6.73"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}